Novartis Ag (NVS) Cash from Restructuring (2018)

Novartis Ag (NVS) posted Cash from Restructuring of -$16.0 million for Q4 2018, up 51.52% sequentially from -$33.0 million in Q3 2018.

Novartis Ag (NVS) Cash from Restructuring (2018) Analysis & Trends

Novartis Ag has reported Cash from Restructuring for 1 years, with the latest figure at -$16.0 million in Q4 2018.

Quarterly Cash from Restructuring changed N/A year-over-year to -$16.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$57.0 million (changed N/A YoY) and the FY2018 annual result came in at -$57.0 million, changed N/A from the prior year.
Cash from Restructuring grew to -$16.0 million in Q4 2018 per NVS's latest filing, from -$33.0 million in the prior quarter.
Over five years, Cash from Restructuring peaked at -$8.0 million in Q2 2018 and troughed at -$33.0 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn

Download Data